HOME > TOP STORIES

TOP STORIES

REGULATORY Japan’s Stimulus Package Likely to Support API Manufacturing Repatriation, Vaccine/Drug Development

April 3, 2020
REGULATORY Gilead-Sponsored Remdesivir Trial Expected to Start This Month: Minister

April 3, 2020
BUSINESS Amgen Kicks Off Stand-Alone Biz in Japan, Eyes Simultaneous Launch of Full Pipeline

April 2, 2020
BUSINESS Fujifilm Launches Avigan Trial with Completion Eyed in June; Sanofi Too to Test Kevzara in Japan

April 1, 2020
BUSINESS Fujifilm Wants to Launch Avigan Trial in Japan by End of This Week, Abe Talks to WHO Chief

March 31, 2020
REGULATORY Global Health Confab Issues Proposals for Regulatory Harmonization in Asia

March 31, 2020
BUSINESS Daiichi Sankyo Files Yescarta, Second CAR-T Therapy in Japan

March 30, 2020
REGULATORY New Stable Supply Panel Wants to Define “Key Drugs” by This Summer

March 30, 2020
REGULATORY PM Abe Says Japan to Start Registration Trial for Avigan for COVID-19, Plans Production Boost

March 30, 2020
REGULATORY Social Security Council at Odds over Future CEA Use, but Agrees to Watch Chuikyo Debate

March 27, 2020
REGULATORY Japan OKs Enhertu, 3 Sakigake Drugs, Beovu, Latuda, and More

March 26, 2020
REGULATORY Pharma, Healthcare Circle See “Off-Year” Drug Re-Pricing Unrealistic amid Coronavirus Crisis

March 25, 2020
BUSINESS Novartis Japan to Shed Oncology Staffers amid Overall Downscaling

March 24, 2020
ACADEMIA Japan to Join NIH-Sponsored COVID-19 Trial for Gilead’s Remdesivir

March 24, 2020
BUSINESS Chugai Mulling Japan Actemra Trial for COVID-19; Sanofi Says No Kevzara Plan for Now

March 24, 2020
REGULATORY Product Coverage Is the Biggest Theme for Off-Year Re-Pricing Debate: MHLW Official

March 23, 2020
BUSINESS (Update) Japan Approves Novartis’ SMA Gene Therapy Zolgensma; 15-20 Patients Expected Annually

March 19, 2020
ACADEMIA Pancreatitis Drug Nafamostat Potentially Effective for COVID-19: Researchers

March 19, 2020
BUSINESS Post-Promotion Guidelines - 1: Drug Makers Struggling to Establish Non-Sales Criteria for Rep Performance Review

March 18, 2020
BUSINESS Fujifilm Plans Company-Sponsored Avigan Trial for COVID-19 in Japan

March 17, 2020

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…